Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 12/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | PTPRC | P08575 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26560867 | 0.93 | PDK2 (0.58) | PDK2ALDH1A1PTPRCMAPK1KDM4E | |
| SCHEMBL30572166 | 0.86 | PTPRC (0.59) | PDK2PTPRCMAPK1KDM4E | |
| SCHEMBL26115268 | 0.86 | PTPRC (0.59) | PDK2PTPRCMAPK1KDM4E | |
| SCHEMBL30571904 | 0.84 | KDM4E (0.44) | PDK2ALDH1A1PTPRCMAPK1KDM4E | |
| SCHEMBL26573272 | 0.84 | KDM4E (0.44) | PDK2ALDH1A1PTPRCMAPK1KDM4E | |
| SCHEMBL26573347 | 0.83 | KDM4E (0.50) | PDK2ALDH1A1PTPRCMAPK1KDM4E | |
| SCHEMBL30572132 | 0.81 | PTPRC (0.69) | ALDH1A1PTPRCMAPK1KDM4EGAA | |
| SCHEMBL30571863 | 0.81 | KDM4E (0.44) | PDK2ALDH1A1PTPRCMAPK1KDM4E | |
| SCHEMBL30571565 | 0.81 | PDK2 (0.56) | PDK2ALDH1A1PTPRCMAPK1KDM4E | |
| SCHEMBL30571474 | 0.80 | MAPK1 (0.44) | PDK2ALDH1A1PTPRCMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | PDK2 3616/4885ALDH1A1 1707/4885PTPRC 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.